Correction to “The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease”
{"title":"Correction to “The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease”","authors":"","doi":"10.1002/trc2.70131","DOIUrl":null,"url":null,"abstract":"<p>Bakker A, Rani N, Moh3 R, Gallagher M. The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in <i>APOE</i> ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease. <i>Alzheimers Dement</i>. 2024;10(4):e70004. doi: 10.1002/trc2.70004.</p><p>In the acknowledgement section the sentence “The authors would also like to thank Ken Payie at KGP-Biotech for the production and manufacture of the extended-release medication, Kevin Arauz at Worldwide Clinical Trials for project management, and Carrie L. Speck at Johns Hopkins University for project coordination” inadvertently left out two people that should be recognized. The sentence should read “<i>The authors would also like to thank Marilyn Albert at Johns Hopkins University for scientific guidance, Kevin Arauz at Worldwide Clinical Trials for project management, Ken Payie at KGP-Biotech for the production and manufacture of the extended-release medication, Sharon Rosenzweig-Lipson at AgeneBio for program development, and Carrie L. Speck at Johns Hopkins University for project coordination</i>.”</p><p>We apologize for this oversight and thank you for your assistance in this matter.</p><p>Arnold Bakker</p>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 3","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70131","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Bakker A, Rani N, Moh3 R, Gallagher M. The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease. Alzheimers Dement. 2024;10(4):e70004. doi: 10.1002/trc2.70004.
In the acknowledgement section the sentence “The authors would also like to thank Ken Payie at KGP-Biotech for the production and manufacture of the extended-release medication, Kevin Arauz at Worldwide Clinical Trials for project management, and Carrie L. Speck at Johns Hopkins University for project coordination” inadvertently left out two people that should be recognized. The sentence should read “The authors would also like to thank Marilyn Albert at Johns Hopkins University for scientific guidance, Kevin Arauz at Worldwide Clinical Trials for project management, Ken Payie at KGP-Biotech for the production and manufacture of the extended-release medication, Sharon Rosenzweig-Lipson at AgeneBio for program development, and Carrie L. Speck at Johns Hopkins University for project coordination.”
We apologize for this oversight and thank you for your assistance in this matter.
期刊介绍：
Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
